A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2009
12/15/2009	US7632803 Metal-binding peptides administered to reduce damage done by reactive oxygen species byby reducing concentration of transition metal ions, particularly copper and iron; antiischemic agents; cardiotonic agents; metal binder-modified tetrapeptides, e.g.porphrins, tetracarboxylic acids; carriers
12/15/2009	US7632802 Reducing the risk of infection in a patient with lowered neutrophil count byadministering an immunostimulant S100 protein; immunosuppressed, chemotherapy-treatedpatients and those having bone marrow transplant; measurement of neutrophil bloodconcentrations; side effect reduction; cost efficiency
12/15/2009	US7632801 Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
12/15/2009	US7632677 Cell line expressing mutated human tissue-type plasminogen activator, the constructing strategy thereof and method of preparing expressed protein
12/15/2009	US7632665 biocatalysis in presence of alcohol dehydrogenase, for reducing acetophenone, 2-chloroacetophenone, 4-chloroacetophenone or 2,3'-dichloro-acetophenone to alcohols
12/15/2009	US7632659 Use of Shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo
12/15/2009	US7632650 Diagnostics and therapeutic uses of topors
12/15/2009	US7632648 Screening a library of potential specific binders with at least one cyclic peptide for identifying specific binding partners for holoTC, having specificity for holoTC over apoTC of at least 40-fold
12/15/2009	US7632646 Tuberculosis diagnostic test
12/15/2009	US7632643 PCA3, PCA3 genes, and methods of use
12/15/2009	US7632514 a universal polypeptidic carrier for targeting molecules to a Gb3 receptor for the B-subunit of Shiga-Toxin expressing cells and its use for intracellular transport and processing of proteins, peptides, oligopeptides, glycoproteins, etc
12/15/2009	US7632513 amino acid sequence of subunit A of a cholera toxin (CT-A) or a fragment of the amino acid sequence of subunit A of an Escherichia coli heat labile toxin (LT-A) or a fragment, where in Ser-63 and Arg-192 are replaced with another amino acid
12/15/2009	US7632512 Use of polynucleotides encoding small acid-soluble spore protein for inhibiting bacterial cell growth and/or treating bacterial infections
12/15/2009	US7632507 Comprises nucleotide sequences coding synoviolin polypeptide for identifying modulators for treatment of arthritic and inflammatory disorders
12/15/2009	US7632503 Using human insulin-like growth factor-1 (IGF-1) fusion protein as therapeutic in treatment and prevention of muscular disorders
12/15/2009	US7632502 Immunoglobulin for diagnosis and prevention of yeast infections
12/15/2009	US7632496 Administering to patient therapeutic dose of cytokine in combination with antibodies directed against tumor associated antigen carbonic anhydrase IX (CAIX/G250/MN); method characterized in significantly reduced cytokine-related toxicity combined with potentiated effectiveness of anti-G250 antibody alone
12/15/2009	US7632495 Administering fibrinogen like protein 2 (fgl2) or a nucleic acid encoding it; preventing graft versus host rejection, autoimmune disease, and allergies; T-cell proliferation inhibitors
12/15/2009	US7632494 Methods for enlarging the diameter of a biological conduit in a human subject
12/15/2009	US7632492 Use of host cells in forming modified target molecules, including therapeutic molecules having non-natural amino acids in their sequence; biosynthesis; drug conjugates
12/15/2009	US7632491 Lyophilized formulations of pegylated interferon which are prepared using trehalose as a cryoprotectant; formulations have a low moisture content, which helps stabilize the pegylated interferon during storage at room temperature
12/15/2009	US7632490 Use of IL-1 antagonists to treat gout
12/15/2009	CA2601208C Method of preventing or treating type 1 diabetes by gene therapy with a secreted form of glutamic acid decarboxylase.
12/15/2009	CA2411968C Protein glycosylation modification in pichia pastoris
12/15/2009	CA2403962C Powdery preparation for transmucosal administration comprising a medicine of high molecular weight and exhibiting an improved storage stability
12/15/2009	CA2386782C Bioadhesive nanoparticulate compositions having cationic surface stabilizers
12/15/2009	CA2361635C Methods and compositions for healing and repair of articular cartilage
12/15/2009	CA2358787C Oil maintenance indicator
12/15/2009	CA2345138C Polymer conjugates of interferon beta-1a and their uses
12/15/2009	CA2344049C Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
12/15/2009	CA2336773C Component b as angiogenic agent in combination with human growth factors
12/15/2009	CA2333125C Alpha emitting constructs and uses thereof
12/15/2009	CA2330545C Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
12/15/2009	CA2294996C Angiotensin derivatives
12/15/2009	CA2269096C Method for in vitro preconditioning of myoblasts before transplantation
12/15/2009	CA2267175C Alpha-9 integrin antagonists and anti-inflammatory compositions thereof
12/15/2009	CA2259185C High dose liposomal aerosol formulations
12/15/2009	CA2248960C Stable factor viii/vwf-complex
12/15/2009	CA2186763C Use of substituted dextranes for treating nervous system damage, and heparane sulphate-enriched fractions
12/15/2009	CA2175319C Use of bovine colostrum extract in mouth-care products
12/10/2009	WO2009149379A2 Use of leptin for the treatment of fatty liver diseases and conditions
12/10/2009	WO2009149377A1 Use of pegylated type iii interferons for the treatment of hepatitis c
12/10/2009	WO2009149368A1 Nasal formulations of insulin
12/10/2009	WO2009149317A2 Transmucosal delivery of therapeutic agents and methods of use thereof
12/10/2009	WO2009149307A2 Compositions and methods for restoring mitochondrial electron transfer function
12/10/2009	WO2009149306A2 Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds
12/10/2009	WO2009149279A2 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
12/10/2009	WO2009149239A1 Methods of modulating angiogenesis via trpv4
12/10/2009	WO2009149179A2 Enhanced antiviral therapy methods and devices
12/10/2009	WO2009149171A2 Fgf21 mutants and uses thereof
12/10/2009	WO2009149161A2 Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
12/10/2009	WO2009149149A1 Prevention or treatment of immune-relevant disease by modification of microfloral populations
12/10/2009	WO2009149148A2 Long-acting glp-1 derivatives, and methods of treating cardiac dysfunction
12/10/2009	WO2009149094A2 Cytotoxic t cell defined egfr peptide and an optimized derivative peptide
12/10/2009	WO2009149012A1 Laidlomycin compositions and methods
12/10/2009	WO2009148954A2 Dosing regimen
12/10/2009	WO2009148947A1 Oligomeric biosurfactants in dermatocosmetic compositions
12/10/2009	WO2009148923A1 Hepatitis c virus inhibitors
12/10/2009	WO2009148896A2 Anti-phospho-akt antibodies
12/10/2009	WO2009148709A1 Pharmacological targeting of vascular malformations
12/10/2009	WO2009148615A1 Cyclosporin analogs and their use in the treatment of hcv infections
12/10/2009	WO2009148583A2 Method for improvement of octreotide bioavailability
12/10/2009	WO2009148580A2 Controlled release copolymer formulation with improved release kinetics
12/10/2009	WO2009148566A2 Development of a c-reactive protein mutant with improved therapeutic benefit in immune thrombocytopenia and lupus nephritis
12/10/2009	WO2009148551A1 Cosmetic compositions
12/10/2009	WO2009148550A1 Biomarkers for painful intervertebral discs and methods of use thereof
12/10/2009	WO2009148343A1 Peptide analogues, particularly for the treatment of chronic pain
12/10/2009	WO2009148299A1 Method to stimulate immune function and regeneration
12/10/2009	WO2009148294A1 Extract from the skin of rana catesbeiana, compound and method for treating mastitis in cattle
12/10/2009	WO2009147368A1 Peptides
12/10/2009	WO2009147331A1 Use of a dead-box rna helicase for inducing cytokine production
12/10/2009	WO2009147326A1 Analgesic effects of peptide toxin apetx2
12/10/2009	WO2009147234A2 Anxiolytic composition containing alphas1-casein-derived peptides
12/10/2009	WO2009146929A1 Stimuli-responsive hydrogel
12/10/2009	WO2009146886A2 Novel antibacterial peptides
12/10/2009	WO2009126950A3 Diterpene glycosides as natural solubilizers
12/10/2009	WO2009124330A3 Treatment of tumors
12/10/2009	WO2009114539A3 Neuroprotective integrin-binding peptide and angiopoietin-1 treatments
12/10/2009	WO2009108760A3 Dendritic macroporous hydrogels prepared by crystal templating
12/10/2009	WO2009103105A3 Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders
12/10/2009	WO2009077857A3 Trail variants for treating cancer
12/10/2009	WO2009054994A3 Use of compounds activating sirt-3 for mimicking exercise
12/10/2009	WO2008134310A8 Stabilization of liquid solutions of recombinant protein for frozen storage
12/10/2009	US20090306776 Methods and procedures for ligament repair
12/10/2009	US20090306707 Joining and/or Sealing Tissues Through Photo-Activated Cross-Linking of Matrix Proteins
12/10/2009	US20090306339 Preparation of Fine Particles
12/10/2009	US20090306192 BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases, and for modulation of cell survival and/or death
12/10/2009	US20090306036 Methods of screening agents, conjugates or conjugate moieties for transport by a pept2 transporter
12/10/2009	US20090306030 Methods Of Inhibiting Osteoclast Activity
12/10/2009	US20090305995 Agonists and antagonists of the somatostatin receptor
12/10/2009	US20090305994 Compounds Modulating Vegf Receptor and Uses Thereof
12/10/2009	US20090305993 Methods and composition for the treatment of gastrointestinal disorders
12/10/2009	US20090305992 Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
12/10/2009	US20090305991 33 Human Secreted Proteins
12/10/2009	US20090305990 Bi-lateral local renal delivery for treating congestive heart failure and for bnp therapy
12/10/2009	US20090305989 Composition and method for potentiating drugs
12/10/2009	US20090305988 Modified peptide of human acidic fibroblast growth factor
12/10/2009	US20090305987 Method For Inducing Beta Cell Neogenesis From Epithelial Cells
12/10/2009	US20090305986 FGF21 Mutants and uses thereof
12/10/2009	US20090305985 Immunomodulatory Agents For Treatment of Inflammatory Diseases

1 ... 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 ... 3163